

GOPEN ACCESS

Citation: Cheng HM, Zhao X, Lim WS, Tan BJM, Tey HL (2021) Factors affecting duration of SARS-Cov-2 viral shedding in mildly symptomatic patients isolated in a community facility. PLoS ONE 16(9): e0257565. https://doi.org/10.1371/journal. pone.0257565

Editor: Robert Jeenchen Chen, Ohio State University Wexner Medical Center Department of Surgery, UNITED STATES

Received: May 20, 2021

Accepted: September 5, 2021

Published: September 27, 2021

Copyright: © 2021 Cheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: HL Tey is supported by the Clinician Scientist Awards (NMRC/CSA-INV/0023/2017 and CSAINV20nov-0003) conferred by Singapore's National Medical Research Council.

Competing interests: The authors have declared that no competing interests exist.

RESEARCH ARTICLE

Factors affecting duration of SARS-Cov-2 viral shedding in mildly symptomatic patients isolated in a community facility

Hui Mei Cheng¹, Xiahong Zhao¹, Wei Shyann Lim², Beatrice Jia Min Tan², Hong Liang Tey^{1,2,3}*

1 National Skin Centre, Singapore, Singapore, 2 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 3 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

* hltey@nsc.com.sg, teyhongliang111@yahoo.com

Abstract

Introduction

Mildly symptomatic cases of Covid-19 in previously-well individuals form the majority of infections and also serve as potent vectors of transmission. The factors affecting the duration of SARS-CoV-2 RNA viral shedding (DVS) in these patients remain largely unknown.

Objectives

To perform a systematic analysis of the clinical, radiologic, laboratory investigations in patients with few comorbidities infected with mild Covid-19 to identify factors associated with the DVS.

Methods

In this retrospective cohort study, patients with mild or asymptomatic Covid-19 were included. Baseline characteristics including age, nationality, comorbidities, concomitant medications, and type of isolation arrangement in the facility (single or in pairs) were collected. Clinical features and radiologic/haematologic findings were also collected. Taking day 28 as the cut-off, 187 patients who had a negative swab result up to day 28 (no prolonged DVS) were compared to 126 patients with a persistently positive result on or after day 28 (prolonged DVS).

Results

Of 964 consecutive patients included, 851 (88.3%) patients were symptomatic. 266 patients had a documented negative RT-PCR assay with a median DVS of 25 days (range: 13 to 96 days; interquartile range (IQR): 22 to 33 days). Patients isolated in pairs were associated with prolonged DVS (OR: 2.7; 95% CI: 1.7 to 4.5; p<0.0001) compared to those isolated individually. Among vital signs, only tachycardia was associated with prolonged DVS (OR: 2.6; 95% CI: 1.0 to 7.1; p = 0.03). Amongst investigations, only a raised CRP was associated with prolonged DVS (OR: 2.7; 95% CI: 1.1 to 6.8; p = 0.02).

Conclusions

In young, mildly symptomatic Covid-19 patients, prolonged DVS was associated with being isolated in pairs compared to individually. In situations where a negative RT-PCR test result is required, retesting in patients who were not isolated individually, or who had baseline tachycardia or a raised CRP, may be delayed to increase the yield of a negative result.

Introduction

Mildly symptomatic cases of Covid-19 form the majority of infections [1] and also serve as potent vectors of transmission [2]. The duration of viral RNA shedding (DVS) in these patients has important public health implications particularly with respect to isolation duration as well as retesting schedule and de-isolation protocols but studies are lacking. In Singapore, an outbreak of Covid-19 clusters in the foreign-worker population residing in worker dormitories led to the development of a large-scale community medical facility [3]. An understanding of the DVS and its determinants in largely well individuals would allow more effective allocation of testing resources to confirm clearance of virus and potentially allow for a stratified de-isolation protocol of these patients. Moreover, despite efforts at vaccination drives underway internationally, the incidence of Covid-19 infection and its associated mortality shows no clear signs of abatement at present [4]. An understanding of DVS remains important in directing preventive measures in addition to vaccination efforts.

The aim of this retrospective cohort study was to describe the characteristics and natural history of disease in healthy individuals with mild Covid-19 infections to determine the factors which affect DVS.

Methods

Patients diagnosed with Covid-19 based on a positive nasopharyngeal swab reverse transcription-polymerase chain reaction (RT-PCR) result for SARS-CoV-2 and admitted from 10 to 17 April 2020 to a community care facility (Singapore EXPO Convention and Exhibition Centre) were included in this retrospective cohort study. As part of the routine clinical management of these patients, all patients underwent repeated nasopharyngeal swab tests at day 14 which was repeated every 3–5 days. Protocol of swabbing differed according to discharge destination. If a patient was discharged to the community, two nasopharyngeal swab PCR tests performed on separate days were required to be negative and no further swabs were performed after this. However, for patients who were transferred to a quarantine facility after a period of observation in this community care facility, negative PCR swab test was not a requirement. Nevertheless, if such patients received two separate negative PCRs, no further swabs were performed.

Baseline characteristics including age, nationality, comorbidities, concomitant medications, and type of isolation arrangement in the facility (single or in pairs) were collected. Presence and nature of symptoms, and baseline vital signs including presence of temperature (T), heart rate (HR), blood pressure (BP) were collected. Fever was defined as $T \ge 37.5C$, tachycardia as HR ≥ 100 . Investigations including chest X-ray (CXR) findings, and the presence of abnormal blood results including anemia, leukopenia, leukocytosis, thrombocytopenia, thrombocytosis, raised inflammatory markers including C-reactive protein (CRP), ferritin, lactate dehydrogenase and transaminitis of liver enzymes were collected.

Nasopharyngeal swabs were obtained by inserting a swab into each nostril to a depth of approximately 5cm, done one side at a time. Viral nucleic acids were extracted by the

laboratory using the the NucliSens EasyMAG instrument (BioMérieux, Marcy-l'Étoile, France). Presence of SARS-CoV-2 was assessed using the Agency for Science, Technology and Research (A*STAR) Fortitude Kit (Accelerate Technologies, Singapore). All tests were performed according to the manufacturer's protocol. A positive RT-PCR test had cycle-threshold (Ct) value of \leq 30.

All variables were summarized descriptively using counts and percentages for variables in nominal scale and mean with standard deviation and median with range for variables in interval/ratio scale. DVS was defined as the time from positive RT-PCR or symptom onset, whichever was earlier, to the date of negative RT-PCR on nasopharyngeal swab. Patients who had a negative swab result up to day 28 (no prolonged DVS) were compared to those with a persistently positive result on or after day 28 (prolonged DVS). Two sample t-test for interval/ratio variables and Fisher's exact test for nominal variables were used to assess the difference. P-value less than 0.05 was considered statistically significant. Odds ratio (OR) was calculated for factors that were significantly associated with prolonged DVS with 95% confidence interval (CI). Statistical analyses were done using R version 3.5.3.

The study was approved by the National Healthcare Group Domain Specific Review Board (Approval ID 2020/00694) and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. Requirement for informed consent was waived by the ethics committee. All data were anonymised at time of access.

Results

Baseline characteristics (Table 1).

All 964 consecutive patients admitted to the facility during the study period were included, all patients were male, with a mean age of 28.8 years old (SD: 4.2), and majority (86.9%) was of Bangladeshi (58.2%) or Indian (28.7%) ethnicity. 95.4% did not have any past medical history and 98.5% were not on any regular medications. Of 33 patients with comorbidities, 7 had hypertension, 4 had asthma, 3 had diabetes mellitus, the remaining had unrelated medical and surgical history (allergic rhinitis, eczema, gastroesophageal reflux disease). Correspondingly, regular medications patients were taking included antihypertensives (amlodipine, bisoprolol, enalapril), diabetic medications (linagliptin, metformin), and medications for asthma or gastroesophageal reflux disease (salbutamol inhaler, proton-pump inhibitors). 49.6% were isolated in a cubicle individually, the remainder were isolated in pairs. Four patients had clinical deterioration and were transferred to a tertiary hospital. None of the patients died from Covid-19 related or unrelated causes at 3 months follow up in July 2020. 266 patients had a documented negative RT-PCR result and median DVS was 25 days (range: 13 to 96 days; interquartile range (IQR): 22 to 33 days). Median DVS was 25 days (range: 13 to 96 days; IQR: 23 to 30 days) among symptomatic patients (n = 243) and 26 days (range: 13 to 79 days) among asymptomatic patients (n = 23) (p = 0.319). On day of discharge (median 34 days; range: 6 to 72 days; IQR: 18 to 36 days), 89.9% (n = 867) reported no symptoms.

Signs and symptoms (Table 1)

851 (88.3%) patients were symptomatic at admission, median length of symptoms was 11 days (range 0 to 45 days, IQR 10 to 15 days). Reported symptoms were fever (60.6%) and upper respiratory tract symptoms (61.3%) including cough, rhinorrhea, sore throat, anosmia, ageusia. Vital signs on admission were largely normal; the most common abnormalities were tachy-cardia (8.4%) and fever (6.8%).

Summary Statistics	All (n = 964)	
Baseline characteristics		
Age (years)		
n; mean (SD)	947; 28.8 (4.2)	
Nationality		
Bangladesh/Indian	821/945 (86.9%)	
Others	46/945 (4.9%)	
Unknown	78/945 (8.3%)	
Comorbidities		
Yes	33/714 (4.6%)	
No	681/714 (95.4%)	
Usual medications		
Yes	11/712 (1.5%)	
No	701/712 (98.5%)	
Single-bed cubicle		
Yes	479 (49.6%)	
No	485 (50.3%)	
Transferred to tertiary hospital		
Yes	4/963 (0.4%)	
No	959/963 (99.6%)	
Duration of Viral Shedding (days)		
n; median (range) (IQR)	266; 25 (13, 96) (22, 33)	
No. of days from diagnosis to discharge		
n; median (range) (IQR)	943; 34 (6, 72) (18, 36)	
Signs and symptoms		
Symptomatic		
Yes	851 (88.3%)	
No	113 (11.7%)	
Symptom duration (days)		
n; median (range) (IQR)	677; 11 (0, 45) (10, 15)	
Symptom (n = 851)		
Fever	478/789 (60.6%)	
Upper respiratory tract symptoms	484/789 (61.3%)	
Headache, myalgia, malaise	143/789 (18.1%)	
Chest pain, dyspnea	14/789 (1.8%)	
Diarrhea	5/789 (0.6%)	
Vital signs		
Fever	65/960 (6.8%)	
Tachycardia	81/961 (8.4%)	
SpO2, % (n; mean [SD])	961; 99.5 (0.8)	
SBP, mmHg (n; mean [SD])	961; 123.8 (11.6)	
DBP, mmHg (n; mean [SD])	961; 81.6 (9.9)	
Investigations		
CXR findings		
Normal	836/948 (88.2%)	
Opacity or haziness	76/948 (8.0%)	
Consolidation	2/948 (0.2%)	
Others	34/948 (3.6%)	

Table 1. Baseline characteristics, signs and symptoms, investigations of all patients.

(Continued)

Table 1. (Continued)

Summary Statistics	All (n = 964)	
Abnormal blood results (n = 352)		
Anemia	17 (4.8%)	
Leukopenia	100 (28.4%)	
Leukocytosis	239 (67.9%)	
Thrombocytopenia	39 (11.1%)	
Thrombocytosis	2 (0.6%)	
Raised CRP	118 (33.5%)	
Raised ferritin	8 (2.3%)	
Raised LDH	23 (6.5%)	
Transaminitis	65 (18.5%)	

https://doi.org/10.1371/journal.pone.0257565.t001

Investigations (Table 1)

CXRs was performed on 948 patients, of which 836 (88.2%) were normal. Frank consolidation was seen in only 2 CXRs, and most abnormal CXRs reported ill-defined opacities or haziness (8.0%). Among blood investigations, leukocytosis (67.9%), raised CRP (33.5%), and leukopenia (28.4%) were the most common abnormalities.

Factors affecting DVS (Table 2)

Taking day 28 as the cut-off, 187 patients who had a negative swab result up to day 28 (no prolonged DVS) were compared to 126 patients with a persistently positive result on or after day 28 (prolonged DVS) to determine factors affecting DVS.

Discussion

Young, male patients with few comorbidities, representative of the foreign worker population diagnosed with mild Covid-19 infections in Singapore, were isolated in a community facility. The median duration of viral shedding was 25 days after disease onset and is longer than previously reported in the literature (median 7–19.5 days) amongst patients with non-severe disease [5, 6]. Possibly attributable to the ethnic and gender bias in our population, the discrepancy may also be contributed by the larger proportion of patients in solitary spaces [5] or the administration of empirical antiviral treatment⁵ in other studies.

We found that more patients isolated in pairs were associated with prolonged DVS than those isolated individually, suggesting that high frequency, close contact amongst positive cases increases DVS. Current WHO guidelines recommend that patients in such isolation facilities be placed in single rooms or at a distance of at least one metre apart [7] but we found that patients isolated under these two conditions experience a significant difference in DVS. As the number of infections continue to increase in many countries [8], isolation facilities play an increasingly important role in containment of mildly symptomatic patients without overwhelming the healthcare system. Whether such a perpetuation in viral exposure results in a higher viral load in individual patients and how this translates into viable live virus capable of transmission remains to be investigated. Current evidence suggests that a positive RT-PCR does not equate to detection of live culture and patient infectivity [9]. However, it remains a widely-used and clear-cut surrogate marker for infectivity. Specifically, a negative RT-PCR test result remains an important requirement for air and cruise travel [10] and entrance into certain public places. Further research into the clinical implications of this prolonged DVS is necessary.

Table 2. Factors affecting duration of viral shedding.

No (no (no (no (no (no (no (no (no (no (n	Summary Statistics	All (n = 313)	Prolonged Duration of Viral Shedding		P-value
InstructionalAgreynoImam (Si)Imam (Si)			No (n = 187)	Yes (n = 126)	
Age (sens)Image (sens)Image (sens)0.45mate (sD)308; 28.7.3.9)184; 28.5.3.6)124; 28.9.4.3.0Banglackhirdan266/312 (85.3%)158/186 (85.6%)10.8.75.%)Chars4.46/954 (3.0%)10.6.5.3%)4.12.2.3.0Uhrson32.712 (10.3%)18/186 (9.7%)4.12.3.0.0Conorbidities0.33Ye12.223 (5.0%)7.129 (5.4%)6.104 (5.5%)-No220.233 (44.4%)122/122 (94.6%)9.8104 (94.2%)-No220.7233 (27.8%)1.1728 (0.8%)4.104 (3.8%)0.18No227.232 (27.8%)1.1728 (0.8%)4.104 (3.8%)0.18No227.232 (27.8%)1.1728 (0.8%)4.104 (3.8%)0.18No227.232 (27.8%)1.1728 (0.8%)4.0104 (96.2%)-Yes191 (6.10%)13.2 (70.6%)59 (3.8%)<		Baseline	characteristics		
nmean (SD)398, 28.7 (3.9)184, 28.5 (3.6)124, 28.9 (4.3)Nationality0.99Nationality158/186 (85.0%)108 (85.7%)Others46/945 (49%)10 (5.3%)4 (2.2%)Others46/945 (49%)10 (5.3%)4 (1.01%)Comorbidities0.93Yes12/233 (5.6%)7/129 (5.4%)6/104 (3.8%)No220233 (4.4%)12/212 (9.6%)98/104 (9.4%)No220233 (4.4%)12/212 (9.6%)4/104 (3.8%)No220233 (4.4%)12/212 (9.6%)4/104 (3.8%)No222732 (27.8%)12/128 (99.2%)100/104 (96.2%)No222732 (27.8%)12/128 (99.2%)100/104 (96.2%)No227132 (10.8%)31.6%)0/125 (0.0%)0.28No </td <td>Age (years)</td> <td></td> <td></td> <td></td> <td>0.45</td>	Age (years)				0.45
Nationality[0.99]Bangladesh/Indian266/312 (85.3%)158/186 (85.6%)108 (85.7%)Bangladesh/Indian266/312 (85.3%)105.3%)4.6.2%)Others32/312 (10.3%)18/186 (9.7%)14 (11.1%)Comorbidities12/233 (50.4%)7/129 (5.4%)61/10 (5.5%)No220/233 (34.4%)12/21/23 (94.6%)9/9/101 (91.2%)No220/233 (34.4%)12/21/29 (94.6%)4/104 (3.8%)0.18No220/233 (24.5%)11/128 (0.8%)4/104 (3.8%)0.18No220/23 (29.5%)12/128 (0.8%)4/104 (3.8%)0.18No2227 (29.0%)12/12 (0.6%)4/104 (3.8%)0.18No122 (29.0%)122 (7.6%)4/104 (3.8%)4<0001	n; mean (SD)	308; 28.7 (3.9)	184; 28.5 (3.6)	124; 28.9 (4.3)	
Banglachs/indian 256(31 (85.3%) 158(86 (56.0%) 41 (01.1%) Others 46/945 (4.9%) 10 (5.3%) 4 (3.2%) Uhknown 52/312 (10.3%) 18(186 (0.7%) 14 (11.1%) 0.93 Comorbidities 12/233 (56.0%) 7/125 (5.4%) 6/104 (5.5%) 1 No 22/02.33 (94.4%) 12/129 (94.6%) 98/104 (94.2%) 0.18 No 22/02.33 (94.4%) 12/128 (99.2%) 10/101 (96.2%) 0.18 Yes 5/32 (2.2%) 11/128 (0.9%) 4/104 (3.8%) 0.18 No 22/723 (97.8%) 12/128 (99.2%) 10/0104 (96.2%) Yes 191 (61.0%) 132 (70.6%) 59 (46.8%) <<0001	Nationality				0.99
Obless 449945 (9.9%) 10 (5.3%) 4 (3.2%) Unknown 32/312 (10.3%) 18/186 (9.7%) 14 (3.2%) Comorbidities 0.33 Yes 12/23 (5.6%) 7/129 (5.4%) 6/104 (5.8%) No 220/233 (94.4%) 122/129 (94.6%) 98/104 (94.2%) Uanal medications - - - Yes 5/232 (2.2%) 1/128 (0.8%) 4/104 (3.8%) 0.18 Single-bed cubice - - - - Yes 191 (61.0%) 132 (70.6%) 99 (46.5%) <0.0001	Bangladeshi/Indian	266/312 (85.3%)	158/186 (85.0%)	108 (85.7%)	
Unknown32/312 (10.3%)18/186 (9.7%)14 (11.4%)	Others	46/945 (4.9%)	10 (5.3%)	4 (3.2%)	
Connorlities(0.93Yes12/233 (5.4%)7/12 (5.4%)6/104 (5.8%)No22/033 (64.4%)12/12 (9.4.6%)9.8 (101 (9.2.%)Yes5/232 (2.8%)11/28 (0.8.%)4/104 (3.8%)0.18No22/73.2 (9.7.%)12/12 (8.0.%)4/104 (3.8%)0.18Single-bclubice100 (104 06.2%)100 (104 06.2%)100 (104 06.2%)Single-bclubice119 (6.1.0%)132 (7.0.6%)55 (9.4.%)67 (53.2%)No112 (19.0.%)55 (9.4.%)0.0125 (0.0.%)0.28No309/312 (99.0%)184 (98.4%)125/125 (100.0%)0.28No309/312 (99.0%)184 (98.4%)125/125 (100.0%)0.28Symptomator28 (9.1.1%)110 (87.3%)0.07Yes285 (9.1.1%)12 (6.4%)110 (87.3%)0.07No28 (9.1.1%)12 (6.4%)110 (87.3%)0.07Yes145 (26.54.1%)14/163 (51.5%)10 (12.7%)0.28Symptomator (n = 28)178/268 (64.4%)10/163 (6.5%)0.28Upper sepiratory tract symptoms178/268 (64.4%)10/163 (6.5%)0.28Diarba72/268 (0.7%)28/163 (0.3%)49/105 (3.8%)0.07Symptomatic (n = 25)12 (64.7%)10/163 (6.5%)0.28Upper sepiratory tract symptoms178/268 (64.7%)10/163 (6.5%)0.28Diarba12/268 (0.7%)28/163 (0.3%)10/102 (3.8%)0.30Symptom Struct (n = 180)12/268 (0.7%)10/163 (0.3%)10/102 (3.8%)Upper sepir	Unknown	32/312 (10.3%)	18/186 (9.7%)	14 (11.1%)	
Yes1/2235 (6.%)7/129 (5.%)6/104 (5.%)No220/233 (9.4.%)122/129 (9.6.%)98/104 (94.2.%)Yes5/523 (2.%)1/128 (9.%)4/104 (3.8%)0.18No227/232 (9.7.%)1/128 (9.9.%)100/104 (96.2.%)0.18Single-bed cabide1111Yes191 (61.0.%)132 (70.6.%)59 (46.8.%)<0.0001	Comorbidities				0.93
No220/233 (94.4%)122/129 (94.6%)98/104 (94.2%)Uaul medicationsVise5/232 (2.2%)1/1/128 (0.8%)4/1/04 (3.8%)0.18No227/232 (97.8%)127/128 (99.2%)100/104 (96.2%)-Single-bectableYee1191 (61.0%)152 (70.6%)59 (46.8%)< 0.001	Yes	12/233 (5.6%)	7/129 (5.4%)	6/104 (5.8%)	
Usual medicationsImage: style	No	220/233 (94.4%)	122/129 (94.6%)	98/104 (94.2%)	
Yes1/128 (0.8%)1/1128 (0.8%)1/104 (3.8%)0.18No22/722 (07.8%)12/7128 (92.9%)100/104 (95.9%)Single-bed cubice11Yes191 (61.0%)132 (70.6%)59 (46.8%)<<0001	Usual medications				
No 227/232 (97.8%) 127/128 (99.2%) 100/104 (96.2%) Single-bd cubicle Single-bd cubicle No 132 (70.6%) 55 (94.4%) 59 (46.8%) <<0.001 No 122 (39.0%) 55 (29.4%) 67 (53.2%) 0.028 Tansfered to tertiary hospital Yes 3/312 (10%) 3 (18.4%A%) 0.0125 (0.0%) 0.28 Singnature Symptomatic Symptomatic Symptomatic Symptomatic Symptomatic 	Yes	5/232 (2.2%)	1/128 (0.8%)	4/104 (3.8%)	0.18
Single-bed ublicleInterfact (1.9%)Interfact (1.9%)Int	No	227/232 (97.8%)	127/128 (99.2%)	100/104 (96.2%)	
Yes 191 (61.0%) 132 (70.6%) 59 (46.8%) < No 122 (30.0%) 55 (29.4%) 67 (53.2%) Transferred to tertiary hospital 3/12 (1.0%) 3 (1.6%) 0/125 (0.0%) 0.28 No 309/312 (99.0%) 184 (98.4%) 125/125 (100.0%) 0.28 Signa ad symptoms 50 200 (10.0%) 0.07 Symptomatic 0.07 0.07 0.07 No 285 (91.1%) 175 (93.6%) 110 (87.3%) 0.07 No 288 (89%) 12 (6.4%) 61/105 (58.1%) 0.07 Symptom aset (n = 285) 61 61/105 (58.1%) 0.72 Upper respiratory tract symptoms 178/268 (66.4%) 109/163 (66.9%) 69/105 (65.7%) 0.28 Diarchea 7/268 (2.6%) 3/163 (1.2%) 4/105 (3.8%) 0.45 Diarchea 7/268 (2.6%) 3/163 (1.2%) 19/105 (1.8.1%) 1.00 Yeps respiratory tract symptoms 178/268 (66.4%) 109/163 (6.8%) 69/105 (55.7%) 0.28 Diarchea 7/268 (2.6%)	Single-bed cubicle				
No 122 (39.0%) 55 (29.4%) 67 (53.2%) Transfered to tertiary hospital	Yes	191 (61.0%)	132 (70.6%)	59 (46.8%)	< 0.0001
Transferred to tertiary hospital Image: metal symptoms Second State Second State </td <td>No</td> <td>122 (39.0%)</td> <td>55 (29.4%)</td> <td>67 (53.2%)</td> <td></td>	No	122 (39.0%)	55 (29.4%)	67 (53.2%)	
Yes 3/312 (1.0%) 3 (1.6%) 0/125 (0.0%) 0.28 No 309/312 (99.0%) 184 (98.4%) 125/125 (100.0%)	Transferred to tertiary hospital				
No 309/312 (99.0%) 184 (98.4%) 125/125 (100.0%) Signs and symptoms	Yes	3/312 (1.0%)	3 (1.6%)	0/125 (0.0%)	0.28
Signs and symptoms Image: Si	No	309/312 (99.0%)	184 (98.4%)	125/125 (100.0%)	
Symptomatic Image: Constraint of the symptom onset (n = 285 (91.1%) 175 (93.6%) 110 (87.3%) 0.07 No 28 (8.9%) 12 (6.4%) 16 (12.7%) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint of the symptom onset (n = 285) Image: Constraint on the symptom onset (n = 285) Image: Constraint on the symptom onset (n = 285) Image: Constraint on the symptom onset (n = 285) Image: Constraint on the symptom onset (n = 185) Image: Constraint on the symptom onset (n = 118) Image: Constraint onset (n = 118) Image: Constraint on the symptom onset (n = 118) Image: Constraint on the symptom onset (n = 118) Image: Constraint on the sympton onset (n = 118) Image: Constraint o	Signs and symptoms	· ·			
Yes 285 (91.1%) 175 (93.6%) 110 (87.3%) 0.07 No 28 (8.9%) 12 (6.4%) 16 (12.7%)	Symptomatic				
No 28 (8.9%) 12 (6.4%) 16 (12.7%) Symptom onset (n = 285)	Yes	285 (91.1%)	175 (93.6%)	110 (87.3%)	0.07
Symptom onset (n = 285) Image: Constraint of the constraint of	No	28 (8.9%)	12 (6.4%)	16 (12.7%)	
Fever 145/268 (54.1%) 84/163 (51.5%) 61/105 (58.1%) 0.72 Upper respiratory tract symptoms 178/268 (66.4%) 109/163 (66.9%) 69/105 (65.7%) 0.28 Chest pain, dyspnea 7/268 (2.6%) 3/163 (1.8%) 4/105 (3.8%) 0.45 Diarrhea 2/268 (0.7%) 0/163 (0.0%) 2/105 (1.9%) 0.15 Headache, myalgia, malaise 47/268 (17.5%) 28/163 (17.2%) 19/105 (18.1%) 1.00 Symptom duration (days)	Symptom onset (n = 285)				
Upper respiratory tract symptoms 178/268 (66.4%) 109/163 (66.9%) 69/105 (65.7%) 0.28 Chest pain, dyspnea 7/268 (2.6%) 3/163 (1.8%) 4/105 (3.8%) 0.45 Diarrhea 2/268 (0.7%) 0/163 (0.0%) 2/105 (1.9%) 0.15 Headache, myalgia, malaise 47/268 (17.5%) 28/163 (17.2%) 19/105 (18.1%) 1.00 Symptom duration (days) 0 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] 0.01 n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] 0.01 Yital signs	Fever	145/268 (54.1%)	84/163 (51.5%)	61/105 (58.1%)	0.72
Chest pain, dyspnea 7/268 (2.6%) 3/163 (1.8%) 4/105 (3.8%) 0.45 Diarrhea 2/268 (0.7%) 0/163 (0.0%) 2/105 (1.9%) 0.15 Headache, myalgia, malaise 47/268 (17.5%) 28/163 (17.2%) 19/105 (18.1%) 1.00 Symptom duration (days) 0.01 0.01 0.01 0.01 n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] 0.01 Yital signs 0.01 13/126 (10.3%) 0.30 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.9 (9.2) 81.8 (10.4) 0.11 Investigations 0 1266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (88.9%) 11/185 (5.9%) 16/121 (13.2%) 0.11 Opacity or haziness 27/306 (88.9%) 1/185 (0.5%) 0/121 (0.0%) 0.11 <td>Upper respiratory tract symptoms</td> <td>178/268 (66.4%)</td> <td>109/163 (66.9%)</td> <td>69/105 (65.7%)</td> <td>0.28</td>	Upper respiratory tract symptoms	178/268 (66.4%)	109/163 (66.9%)	69/105 (65.7%)	0.28
Diarrhea 2/268 (0.7%) 0/163 (0.0%) 2/105 (1.9%) 0.15 Headache, myalgia, malaise 47/268 (17.5%) 28/163 (17.2%) 19/105 (18.1%) 1.00 Symptom duration (days) 0.01 0.01 0.01 n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] 0.01 Vital signs	Chest pain, dyspnea	7/268 (2.6%)	3/163 (1.8%)	4/105 (3.8%)	0.45
Headache, myalgia, malaise 47/268 (17.5%) 28/163 (17.2%) 19/105 (18.1%) 1.00 Symptom duration (days) . . 0.01 n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] . Vital signs Fever 26/312 (8.3%) 13/186 (7.0%) 13/126 (10.3%) 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations Opacity or haziness 27/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) .	Diarrhea	2/268 (0.7%)	0/163 (0.0%)	2/105 (1.9%)	0.15
Symptom duration (days) 0.01 n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] Vital signs Fever 26/312 (8.3%) 13/186 (7.0%) 13/126 (10.3%) 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 91.4 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations CXR findings Normal 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others	Headache, myalgia, malaise	47/268 (17.5%)	28/163 (17.2%)	19/105 (18.1%)	1.00
n; median (range) [IQR] 222; 11 (3, 44) [9, 14] 136; 10 (3, 38) [8, 13] 86; 11 (6, 44) [10, 18] Vital signs Fever 26/312 (8.3%) 13/186 (7.0%) 13/126 (10.3%) 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations CXR findings Normal 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others 12/306 (3.9%) 7/185 (Symptom duration (days)				0.01
Vital signs 26/312 (8.3%) 13/186 (7.0%) 13/126 (10.3%) 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations 0.11 CXR findings 0.11 Opacity or haziness 27/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (3.8%) 11/185 (5.9%) 16/121 (13.2%) Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72	n; median (range) [IQR]	222; 11 (3, 44) [9, 14]	136; 10 (3, 38) [8, 13]	86; 11 (6, 44) [10, 18]	
Fever 26/312 (8.3%) 13/186 (7.0%) 13/126 (10.3%) 0.30 Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations	Vital signs				
Tachycardia 24/312 (7.7%) 9/186 (4.8%) 15/126 (11.9%) 0.03 SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations CXR findings Normal 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 100	Fever	26/312 (8.3%)	13/186 (7.0%)	13/126 (10.3%)	0.30
SpO2, % (n; mean [SD]) 312; 99.5 (0.9) 186; 99.5 (0.9) 99.5 (0.8) 1.00 SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations	Tachycardia	24/312 (7.7%)	9/186 (4.8%)	15/126 (11.9%)	0.03
SBP, mmHg (n; mean [SD]) 312; 124.2 (11.5) 186; 124.1 (11.6) 124.4 (11.4) 0.79 DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations Image: CXR findings Im	SpO2, % (n; mean [SD])	312; 99.5 (0.9)	186; 99.5 (0.9)	99.5 (0.8)	1.00
DBP, mmHg (n; mean [SD]) 312; 80.8 (9.7) 186; 80.0 (9.2) 81.8 (10.4) 0.11 Investigations 0.11 Investigations 0.11 CXR findings	SBP, mmHg (n; mean [SD])	312; 124.2 (11.5)	186; 124.1 (11.6)	124.4 (11.4)	0.79
Investigations Investigations Investigations Investigations CXR findings 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Normal 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) 0 Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) 0 Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) 0 Ahnormal blood results (n = 118) 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 100	DBP, mmHg (n; mean [SD])	312; 80.8 (9.7)	186; 80.0 (9.2)	81.8 (10.4)	0.11
CXR findings COMPARING Comparison of the comparison of t	Investigations	·			
Normal 266/306 (86.9%) 166/185 (89.7%) 100/121 (82.6%) 0.11 Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Abnormal blood results (n = 118) Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 100	CXR findings				
Opacity or haziness 27/306 (8.8%) 11/185 (5.9%) 16/121 (13.2%) Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Abnormal blood results (n = 118)	Normal	266/306 (86.9%)	166/185 (89.7%)	100/121 (82.6%)	0.11
Consolidation (Unilateral) 1/306 (0.3%) 1/185 (0.5%) 0/121 (0.0%) Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Abnormal blood results (n = 118) Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 1 00	Opacity or haziness	27/306 (8.8%)	11/185 (5.9%)	16/121 (13.2%)	
Others 12/306 (3.9%) 7/185 (3.8%) 5/121 (4.1%) Abnormal blood results (n = 118) 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 100	Consolidation (Unilateral)	1/306 (0.3%)	1/185 (0.5%)	0/121 (0.0%)	
Abnormal blood results (n = 118) Image: Abnormal blood results (n = 118) Image: Abnormal blood results (n = 118) Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 100	Others	12/306 (3.9%)	7/185 (3.8%)	5/121 (4.1%)	
Anemia 10/118 (8.5%) 8/82 (9.8%) 2/36 (5.6%) 0.72 Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 1 00	Abnormal blood results (n = 118)				
Leukocytopenia 33/118 (28.0%) 23/82 (28.0%) 10/36 (27.8%) 1 00	Anemia	10/118 (8.5%)	8/82 (9.8%)	2/36 (5.6%)	0.72
	Leukocytopenia	33/118 (28.0%)	23/82 (28.0%)	10/36 (27.8%)	1.00

(Continued)

Summary Statistics	All (n = 313)	Prolonged Duration of Viral Shedding		P-value
		No (n = 187)	Yes (n = 126)	
Leukocytosis	79/118 (66.9%)	54/82 (65.9%)	25/36 (69.4%)	0.83
Thrombocytopenia	15/118 (12.7%)	10/82 (12.2%)	5/36 (13.9%)	0.77
Thrombocytosis	1/118 (0.8%)	1/82 (1.2%)	0/36 (0.0%)	1.00
Raised CRP	37/118 (31.4%)	20/82 (24.4%)	17/36 (47.2%)	0.02
Raised ferritin	3/118 (2.5%)	2/82 (2.4%)	1/36 (2.8%)	1.00
Raised LDH	5/118 (4.2%)	3/82 (3.7%)	2/36 (5.6%)	0.64
Transaminitis	20/118 (16.9%)	11/82 (13.4%)	9/36 (25.0%)	0.18

Table 2. (Continued)

Age, nationality, presence of comorbidities or concomitant medications did not affect DVS (all p>0.05). Patients isolated in pairs were associated with prolonged DVS (OR: 2.7; 95% CI: 1.7 to 4.5; p<0.0001) compared to those isolated individually. The median (IQR) DVS of patients isolated in pairs was 24 days (23–25), 4 days longer than those isolated individually, with a median of 20 days (17–23). Longer length of symptom duration was associated with prolonged DVS (OR: 1.1; 95% CI: 1.0 to 1.1; p = 0.01) but individual symptoms, type of symptoms, and total number of symptoms were not. Amongst vital signs, only tachycardia was associated with prolonged DVS (OR: 2.6; 95% CI: 1.0 to 7.1; p = 0.03). Amongst blood result abnormalities, only raised CRP was associated with prolonged DVS (OR: 2.7; 95% CI: 1.1 to 6.8; p = 0.02).

https://doi.org/10.1371/journal.pone.0257565.t002

In hospitalised patients, corticosteroid administration, presence of fever, and longer time of disease onset to hospitalisation was associated with prolonged DVS [11]. Studies of an older aged population (median age of 81) also found that DVS was significantly longer in the older age group >65 years [12] and >80 years [13], respectively. Similar to previous studies in asymptomatic/pauci-symptomatic populations, our results revealed that being symptomatic or not did not predict DVS [5, 6]. Unlike in our study in which baseline tachycardia and a raised CRP was associated with a prolonged DVS, these were not observed in a previous study [5].

Limitations of the study include the population's uniform gender and ethnicity which may restrict its external validity. RT-PCR results was reported as binary findings without cycle threshold values and there was a lack of standardised RT-PCR testing schedule protocol although this was likely reflective of real-world practice.

Conclusion

In summary, in our cohort of young male adults with mild Covid-19 disease, prolonged DVS was strongly associated with being isolated in pairs compared to individually. Tachycardia, and raised CRP were also associated with prolonged DVS but presence or absence of symptoms was not. Our data suggests a risk in using resolution of symptoms as the basis of discharging patients from isolation particularly when DVS can be prolonged in young, mildly symptomatic patients isolated in closed proximity to each other. In countries with sufficient testing capacity and in situations where a negative RT-PCR test result is required, retesting in patients who were not isolated individually, or who had baseline tachycardia or a raised CRP can be postponed to conserve limited laboratory supplies and to increase the yield of a negative result.

Supporting information

S1 File. Minimal underlying dataset. (CSV)

Acknowledgments

We thank Ernest Kwek Beng Kee and Ernest Lim Tian Hong from Woodlands Health Campus, Singapore, for their administrative facilitation during conduct of the study.

Author Contributions

Conceptualization: Hui Mei Cheng, Hong Liang Tey.

Data curation: Hui Mei Cheng, Xiahong Zhao, Wei Shyann Lim, Beatrice Jia Min Tan.

Formal analysis: Xiahong Zhao, Wei Shyann Lim, Beatrice Jia Min Tan, Hong Liang Tey.

Investigation: Hui Mei Cheng, Wei Shyann Lim.

Methodology: Hui Mei Cheng, Xiahong Zhao, Wei Shyann Lim, Beatrice Jia Min Tan, Hong Liang Tey.

Supervision: Hui Mei Cheng, Hong Liang Tey.

Validation: Hui Mei Cheng.

Writing - original draft: Hui Mei Cheng.

Writing – review & editing: Hui Mei Cheng, Xiahong Zhao, Wei Shyann Lim, Beatrice Jia Min Tan, Hong Liang Tey.

References

- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239–42. https://doi.org/10.1001/jama.2020. 2648 PMID: 32091533
- Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science (New York, NY). 2020; 368 (6490):489–93. Epub 2020/03/18. https://doi.org/10.1126/science.abb3221 PMID: 32179701; PubMed Central PMCID: PMC7164387.
- Goei A, Mohan Tiruchittampalam GDHM, Leadership F. Community Care Facility—A Novel Concept to Deal With the COVID-19 Pandemic: A Singaporean Institution's Experience. Journal of Public Health Management and Practice. 2020; 26(6):613–21. https://doi.org/10.1097/PHH.000000000001257 00124784-202011000-00018. PMID: 32969951
- World Health Organization. Coronavirus disease (COVID-19) Dashboard 2021. Available from: https:// covid19.who.int/.
- Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Internal Medicine. 2020; 180(11):1447–52. <u>https://doi.org/10.1001/jamainternmed.2020.3862</u> PMID: 32780793
- Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and Symptomatic Patients With Nonsevere Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study. Frontiers in Microbiology. 2020; 11(1570). https://doi.org/10.3389/ fmicb.2020.01570 PMID: 32754137
- World Health Organization. Repurposing facilities for isolation and management of mild COVID-19 cases 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/332273/WPR-DSE-2020-006-eng.pdf?sequence=1&isAllowed=y.
- World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465–9. https://doi.org/10.1038/ s41586-020-2196-x PMID: 32235945
- Centers for Disease Control and Prevention. Testing and International Air Travel 2020 [22/11/2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/travelers/testing-air-travel.html.

- Li TZ, Cao ZH, Chen Y, Cai MT, Zhang LY, Xu H, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol. 2020. Epub 2020/ 07/10. https://doi.org/10.1002/jmv.26280 PMID: 32644223; PubMed Central PMCID: PMC7362127.
- 12. Ueno A, Kawasuji H, Miyajima Y, Fukui Y, Sakamaki I, Saito M, et al. Prolonged viral clearance of severe acute respiratory syndrome coronavirus 2 in the older aged population. Journal of Infection and Chemotherapy. 2021. https://doi.org/10.1016/j.jiac.2021.03.007 PMID: 33781692
- Mancuso P, Venturelli F, Vicentini M, Perilli C, Larosa E, Bisaccia E, et al. Temporal profile and determinants of viral shedding and of viral clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive subjects: a population-based prospective cohort study in Reggio Emilia, Italy. BMJ Open. 2020; 10(8):e040380. https://doi.org/10.1136/bmjopen-2020-040380 PMID: 32878768